Switzerland’s AB2 Bio Bags Nippon Shinyaku As Late-Stage IL-18 Inhibitor Partner

CEO Djordje Filipovic tells Scrip that after talks with "multiple other potential partners,” the firm chose the Japanese group for its expertise and marketing capabilities in rare diseases” to be the licensing partner for tadekinig alfa in the US.